While bowel function is the butt of many a bad joke, for those who suffer from IBS (irritable bowel syndrome) it is no laughing matter. Lotonex - a new drug from Glaxo-Wellcome - promises relief to the 20% of adults who are estimated to suffer from this painful and often stress-related condition. Unlike existing treatments, the active ingredient (called Alosetron) acts directly on serotonin receptor sites in the nervous system. This reduces the sensitivity of the gut, alleviating the chronic abdominal pain and diarrhoea which characterise many cases of IBS. What's more, the drug has few side effects, though it can cause constipation. Lotonex is currently undergoing advance clinical trials in the US and should be available there next year, but European approval is unlikely to be granted before 2001. When it does arrive, however, sales are predicted to be brisk.
Nakul Sharma is the founder of Hostmaker, which manages lettings on behalf of their owners.
Feeling threatened by the new kids on the block? Unruly co-founder Sarah Wood shares the small steps for leaders that will bring about big changes.
Antoine Frérot tells MT about his plans to grow the French utilities giant, the importance of the 'circular economy' and why more leaders should get into art.
Entrepreneurs can't change the macro environment so knuckle down and stay alert, says Paul Lindley.
The social media giant has spent an undisclosed amount on TBH, which lets teens send anonymous compliments to each other.
Brexit won't mean you can ignore the new EU data protection regime.